Expert Opin Biol Ther. 2025 Jan;25(1):133-138. doi: 10.1080/14712598.2024.2426637.Epub 2024 Nov 11.

Stanley Cohen ¹, Shaun Bender ², Amy Shaberman ², Richard Vinisko ², Dottie McCabe ²

Author information

¹Metroplex Clinical Research Center, Dallas, TX, USA.

²Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.

Abstract

Objectives: This analysis reported the incidence of safety endpoints across five phase 3 randomized controlled clinical trials in patients with rheumatoid arthritis (RA), Crohn's disease (CD), and chronic plaque psoriasis (PsO) who received ≥ 1 dose of adalimumab-adbm or adalimumab reference product (RP).

Methods: Exposure-adjusted incidence rates for safety endpoints were calculated per 100 patient-years and reported by disease indication and treatment arm. Subgroup analyses by patient age and sex were also conducted.

Results: The mean length of follow-up was 62 weeks, 48 weeks, and 32 weeks for patients with RA, CD, and PsO, respectively. Rates of serious adverse events (SAEs) and discontinuations due to adverse events (AEs) were similar among patients with RA and PsO, but slightly higher among those with CD. Incidence rates of all safety endpoints were consistent between the adalimumab-adbm and adalimumab RP treatment arms within each indication Subgroup analyses of patients with RA, CD, and PsO showed no between-group differences by age and sex.

Conclusions: In patients with RA, CD, and PsO, there were no differences between biosimilar adalimumab-adbm or the adalimumab RP regarding the rate of AEs, SAEs, discontinuations due to AEs, deaths, or any AEs of special interest.